These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24796368)

  • 1. Insulin pump-associated adverse events in children and adolescents--a prospective study.
    Wheeler BJ; Heels K; Donaghue KC; Reith DM; Ambler GR
    Diabetes Technol Ther; 2014 Sep; 16(9):558-62. PubMed ID: 24796368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family perceptions of insulin pump adverse events in children and adolescents.
    Wheeler BJ; Donaghue KC; Heels K; Ambler GR
    Diabetes Technol Ther; 2014 Apr; 16(4):204-7. PubMed ID: 24313790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type.
    Ross P; Gray AR; Milburn J; Kumarasamy IM; Wu F; Farrand S; Armishaw J; Wiltshire E; Rayns J; Tomlinson P; Wheeler BJ
    Acta Diabetol; 2016 Dec; 53(6):991-998. PubMed ID: 27585938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1].
    Jarosz-Chobot P
    Wiad Lek; 2004; 57(5-6):263-6. PubMed ID: 15518073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical review: insulin pump-associated adverse events in adults and children.
    Ross PL; Milburn J; Reith DM; Wiltshire E; Wheeler BJ
    Acta Diabetol; 2015 Dec; 52(6):1017-24. PubMed ID: 26092321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin pump treatment; increasing prevalence, and predictors for better metabolic outcome in Danish children and adolescents with type 1 diabetes.
    Olsen B; Johannesen J; Fredheim S; Svensson J;
    Pediatr Diabetes; 2015 Jun; 16(4):256-62. PubMed ID: 25082292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
    Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R
    Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin Pump-Associated Adverse Events in a Brazilian Reference Center for the Treatment of Diabetes Mellitus: Proposal for a Taxonomy of Device Failures in Adults, Adolescents, and Children.
    Neves ALD; Martins LEG; Gabbay MAL; Cavicchioli G; Tenorio FS; Cunha TS
    J Diabetes Sci Technol; 2024 Jan; 18(1):74-81. PubMed ID: 35771027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.
    Pickup JC; Yemane N; Brackenridge A; Pender S
    Diabetes Technol Ther; 2014 Mar; 16(3):145-9. PubMed ID: 24180294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre randomized controlled trial of an empowerment-inspired intervention for adolescents starting continuous subcutaneous insulin infusion--a study protocol.
    Brorsson AL; Leksell J; Viklund G; Lindholm Olinder A
    BMC Pediatr; 2013 Dec; 13():212. PubMed ID: 24354899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: A 1-year prospective observational study with suggestions to minimize clinical impact.
    Rabbone I; Minuto N; Toni S; Lombardo F; Iafusco D; Marigliano M; Schiaffini R; Maltoni G; Frongia AP; Scardapane M; Nicolucci A; Cherubini V; Bonfanti R; Scaramuzza AE;
    Diabetes Obes Metab; 2018 Nov; 20(11):2551-2556. PubMed ID: 29893044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes.
    Binder E; Lange O; Edlinger M; Meraner D; Abt D; Moser C; Steichen E; Hofer SE
    Exp Clin Endocrinol Diabetes; 2015 Apr; 123(4):260-4. PubMed ID: 25607337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines concerning insulin dosage in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion].
    Szypowska A; Pańkowska E; Lipka M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):45-50. PubMed ID: 16704861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new reusable insulin pen (ClikSTAR) in Canadian patients with type 1 and type 2 diabetes mellitus receiving insulin glargine.
    Gottesman I; Perron P; Berard L; Stewart J; Basso N; Mettimano K; Elliott T
    Diabetes Technol Ther; 2012 Oct; 14(10):926-35. PubMed ID: 22775367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic control with insulin pump therapy: the Waikato experience.
    Reda E; Von Reitzenstein A; Dunn P
    N Z Med J; 2007 Jan; 120(1248):U2401. PubMed ID: 17277817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.